Regeneron Announces Advances in Novel COVID-19 Antibody Program

Advertisements Regeneron has identified hundreds of virus-neutralizing antibodies; plans to initiate large-scale manufacturing by mid-April with antibody cocktail therapy Potential to enter human clinical studies by early summer This program is in addition to Regeneron’s separate ongoing clinical program evaluating Kevzara® (sarilumab, an IL-6 receptor antibody) in severe COVID-19 patients [mstock id=”72360″] Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today […]